Law360, New York (October 15, 2009, 6:08 PM ET) -- Skandia Life Insurance Co. Ltd. has become the latest party to request lead plaintiff status in a consolidated derivative lawsuit accusing Pfizer Inc. executives of harming the company by promoting prescription drugs for unapproved off-label uses.
In a memorandum filed Wednesday in the U.S. District Court for the Southern District of New York, Skandia claims that, as a large institutional investor holding about 2.1 million Pfizer shares, “it is compelled ... to litigate this action as efficiently and effectively as possible.”
The company also contends that...
Skandia Joins Race For Lead Status In Pfizer Case
To view the full article, take a free trial now.
